Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals had revenue of $2.00B in the twelve months ending March 31, 2024, with 75.20% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $494.33M with 54.82% year-over-year growth. In the year 2023, Alnylam Pharmaceuticals had annual revenue of $1.83B with 76.23% growth.

• Revenue (ttm): $2.00B
• Revenue Growth: +75.20%
• P/S Ratio: 9.49
• Revenue / Employee: $953,969
• Employees: 2,100
• Market Cap: 19.01B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	1.83B	790.87M	76.23%
Dec 31, 2022	1.04B	193.13M	22.88%
Dec 31, 2021	844.29M	351.43M	71.31%
Dec 31, 2020	492.85M	273.10M	124.28%
Dec 31, 2019	219.75M	144.84M	193.36%
Dec 31, 2018	74.91M	-15.00M	-16.69%
Dec 31, 2017	89.91M	42.75M	90.66%
Dec 31, 2016	47.16M	6.06M	14.75%
Dec 31, 2015	41.10M	-9.46M	-18.72%
Dec 31, 2014	50.56M	3.39M	7.20%
Dec 31, 2013	47.17M	-19.56M	-29.31%
Dec 31, 2012	66.73M	-16.03M	-19.37%
Dec 31, 2011	82.76M	-17.28M	-17.28%
Dec 31, 2010	100.04M	-492.00K	-0.49%
Dec 31, 2009	100.53M	4.37M	4.54%
Dec 31, 2008	96.16M	45.27M	88.94%
Dec 31, 2007	50.90M	23.97M	89.00%
Dec 31, 2006	26.93M	21.21M	371.13%
Dec 31, 2005	5.72M	1.44M	33.61%
Dec 31, 2004	4.28M	4.10M	2,330.68%
Dec 31, 2003	176.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.